Drug approvals boost Japanese migraine treatment online | Health Care Asia Magazine

Drug approvals boost Japanese migraine treatment online

Some players have been highly active in digital channels of various countries.

Although digital activity in Japan’s migraine treatment landscape has not been prominent in the country until recently, it is expected to evolve with recent drug approvals, according to a report from GlobalData.

The market size of migraine in Japan is estimated to grow at a compound annual growth rate of 7.97% from $165m in 2021 to $365m in 2029. The landscape is growing with the recent approval of calcitonin gene-related peptide (CGRP) inhibitors as a preventative treatment.

Under the acute treatment market, triptans are the most prescribed drugs and account for most of the sales. However, they have all lost patent protection and are highly genericized across all the major markets. In the preventative market, the most prescribed drugs are beta-blockers while CGRP inhibitors represent the novel class.

Some players in the market have been highly active across digital channels of various countries to promote themselves and offer support to patients and healthcare providers, noted GlobalData’s pharma analyst Venkat Kartheek Vale.

Thus, successful implementation of this strategy in Japan will help companies position their products strongly against each other, Vale said.

However, a lack of diagnostic tools for identifying migraines has been a challenge for physicians to make an accurate and fast diagnosis, showing a need for greater awareness of the indication by healthcare providers to follow an effective treatment approach.

Still, the migraine treatment market is expected to rise with the launch of recent anti-CGRPs and few other novel molecules in the late-stage pipeline, Vale said.

Get Health Care Asia Magazine in your inbox
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

The majority of the country’s pharma manufacturing produces generic drugs.
This is expected to affect local pharma growth in the short term.
Nonetheless, more than half of the age group found its use to be comfortable.
The group’s profits after tax ballooned by as much as 138.4%.
Funds will be used to build out its behavioural health and chronic care modules.
Some players have been highly active in digital channels of various countries.
It has also formed a JV with Acurio to develop a private hospital in NSW.
With this, the company now offers an all-in-one patient management service.
The therapy can be done in eight different languages.
The country is expected to have one in five of its population to be elderly by 2050.
Sunway is planning to ramp up its hospital capacity to about 3,000 beds.
The system will help city managers to track epidemic conditions, real-time.
It is funded through the 2020 Primary Healthcare Research Data Infrastructure grants.
The hospital features 200 general inpatient beds and 100 hemodialysis beds.
The platform expanded its services after obtaining an internet hospital license.